Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We Are Not Done Yet

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2015.00161
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Targeting the Ras/Raf/Mek/Erk Pathway in Hepatocellular Carcinoma (Review)

Oncology Letters
Cancer ResearchOncology
2017English

Prohibitins Role in Cellular Survival Through Ras-Raf-Mek-Erk Pathway

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2014English

Modulation of the Akt/Ras/Raf/Mek/Erk Pathway by A3 Adenosine Receptor

Purinergic Signalling
Molecular NeuroscienceCell BiologyMolecular BiologyCellular
2006English

Targeting Alterations in the RAF–MEK Pathway

Cancer Discovery
Oncology
2019English

Astragaloside IV Attenuates Glutamate-Induced Neurotoxicity in PC12 Cells Through Raf-Mek-Erk Pathway

PLoS ONE
Multidisciplinary
2015English

Molecular Signaling in Multiple Myeloma: Association of RAS/RAF Mutations and MEK/ERK Pathway Activation

Oncogenesis
Cancer ResearchMolecular Biology
2017English

Why Do We Need a New BRAF-MEK Inhibitor Combination in Melanoma?

Oncology in Clinical Practice
Oncology
2019English

Norcantharidin Induces Growth Inhibition and Apoptosis of Glioma Cells by Blocking the Raf/Mek/Erk Pathway

World Journal of Surgical Oncology
SurgeryOncology
2014English

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy